Policies to promote affordability and access across the life cycle of costly new drugs.
Where this comes from
- Record sourced from PubMed, PMID 41218975.
- Also identified by DOI 10.1136/bmj-2025-086516 and PMC identifier 12599526.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, argue <b>Krista Kruja and colleagues</b>